CTRC (chymotrypsin C) is a serine-type endopeptidase that regulates pancreatic enzyme activation through targeted proteolysis of trypsinogens and procarboxypeptidases 1. The enzyme exhibits chymotrypsin-type protease activity and contributes to intracellular calcium ion homeostasis 1. CTRC functions as a disease-predisposing gene rather than a disease-causing gene in chr1 pancreatitis (CP) pathogenesis 2. Pathogenic and likely-pathogenic variants in CTRC are identified in approximately 37.1% of CP patients in European Russian populations 3, with variants such as c.180C>T, c.760C>T, and c.738_761del24 demonstrating elevated odds ratios for disease development 3. CTRC variants significantly influence the age of disease onset and clinical outcomes including pancreatic stones, diabetes mellitus, and steatorrhea, with mutation-positive patients showing earlier median disease onset than mutation-negative patients 4. The gene is typically implicated in oligogenic disease where multiple genetic variants interact with environmental factors (alcohol, smoking) to precipitate disease 15. Clinical interpretation of CTRC variants requires functional evidence and comparison of allelic frequencies between affected and control populations 6. CTRC represents one of the four major genetic risk factors for idiopathic chr1 pancreatitis 1.